Tem sido demonstrado que a redução da sensibilidade do barorreflexo é um marcador independente de risco de mortalidade. O barorreflexo arterial tem um papel importante na manutenção e na estabilidade da pressão arterial (PA) momento a momento. Embora a variabilidade da pressão arterial (VPA) seja conhecida como contribuinte para a morbidade e mortalidade, os mecanismos pelos quais a VPA causa lesões de órgãos alvo ainda não estão bem entendidos. No presente estudo, testamos a hipótese de que o prejuízo do barorreflexo, com ou sem o aumento da PA, pode induzir o remodelamento cardíaco e da artéria pulmonar por alterar a modulação autonômica comandada pelos barorreceptores arteriais sobre coração e vasos. Para tanto, foi investigado em ratos normotensos e hipertensos o efeito da disfunção barorreflexa (10 semanas após desnervação sinoaórtica- DSA) nas alterações hemodinâmicas, no remodelamento cardíaco e no remodelamento da artéria pulmonar. A função e a morfologia cardíaca de ratos machos Wistar e SHR (GN e GH) foram avaliadas pelo ecocardiograma e por histologia. A pressão arterial foi gravada diretamente. A hipertrofia ventricular foi expressa pela relação entre peso doventrículo esquerdo (VE) e peso do ventrículo direito (VD) pelo peso corporal do rato (PC). A VPA foi avaliada pelo domínio do tempo e da freqüência. A expressão gênica pela quantificação do mRNA do peptídio natriurérito (ANP), da alfa-actina esquelética (-actina), do colágeno tipo I e tipo III foi avaliada pelo RT-PCR. A PA estava maior no grupo SHR quando comparada ao normotenso, mas a DSA não alterou os valores de PA nos grupos normotenso e hipertenso. A VPA sistólica mostrou-se maior nos grupos com DSA. Como esperado, a resposta barorreflexa estava reduzida nos grupos com DSA. Os componentes LF e HF da VFC estavam maiores nos grupos GH e GHD. Entretanto, o componente HF da VFC estava menor em GHD quando comparado ao GH. O tempo de aceleração da artéria pulmonar estava reduzido nos grupos com DSA. Adicionalmente, a DSA prejudicou a função diastólica no VE: (GN: 5,80,19 vs GD: 8,00,29 e GH: 8,20,54 vs GHD: 13,50,84 mmHg) e no VD (GN: 3,50,15 vs WD: 4,850,15 e HC: 5,830,31 vs HD: 7,770,25 mmHg). A DSA induziu hipertrofia ventricular direita e esquerda de acordo com o índice de VE e VD/ PC (9% no GD e 10% no GHD) e (25% no GD e 34% no GHD) respectivamente, bem como a DSA induziu aumento de colágeno no VE (de 1,6-vezes no GD e 2-vezes no GHD), no VD (2,9-vezes no GD e 1,15-vezes no GHD), e na artéria pulmonar (3,38-vezes no GD e 1,53-vezes no GHD). Além disso, a DSA aumentou a expressão de colágeno tipo I no VE (6,7-vezes no GD e 1,6-vezes no GHD) e VD (5,7-vezes no GD e 5,3-vezes no GHD); de colágeno tipo III no VE (3-vezes no GD e 2-vezes no GHD) e VD (4,6-vezes no GD e 2,4-vezes no HD). A desnervação aumentou, nos ratos normotensos, a expressão de ANP no VE (1,8-vezes) e no VD (1,8-vezes), de -actina no VE (3,7-vezes) e VD (1,2-vezes). Entretanto, apenas o grupo GHD aumentou a expressão de -actina no VD (1,9-vezes). Nossos resultados demonstraram que o prejuízo da função barorreflexa ocasionado pela DSA, sem modificações na PA, induziu importantes ajustes na estrutura cardíaca caracterizados pela hipertrofia do VE e do VD, bem como na indução da hipertensão pulmonar. Estas mudanças podem sugerir que a disfunção barorreflexa isolada pode modular lesões de tecidos alvo / It has been demonstrated that reduced baroreflex sensitivity is an independent marker of mortality risk. The arterial baroreflex plays an important role in the maintenance of the moment-to-moment stability of blood pressure (BP). Although the contribution of blood pressure variability (BPV) to cardiovascular morbidity and mortality is well established, the mechanisms by which BPV causes end-organ damage process are still unknown. In the present study, we hypothesized that baroreflex impairment, with or without increase in BP, can induce cardiac and pulmonary artery remodeling by altering the autonomic modulation controlled by the arterial baroreceptors to the heart and vessels. For these purposes, it were investigated in normotensive and hypertensive rats the effects of baroreceptors dysfunction (10 weeks after sinoaortic denervation - SAD) on hemodynamic alterations and on cardiac and pulmonary arterial remodeling. Cardiac function and morphology of male normotensive Wistar (GN) and spontaneously hyperntensive (GH) intact rats which underwent SAD (GD and GHD, respectively) were assessed by echocardiography and histology. BP was directly recorded. Ventricular hypertrophy was quantified by the ratio of left ventricular weight (LVW) and right ventricular weight (RVW) to body weight (BW). BPV was quantified in the time and frequency domains. The natriuretic peptide (ANP), alpha-skeletal actin (-skelectal), collagen type I and type III genes mRNA expressions were evaluated by RT-PCR. SHR presented higher BP than Wistar rats, but SAD did not change BP values either in normotensive or in hypertensive groups. Systolic BPV was increased in both SAD groups. As expected, baroreflex responses were reduced in both SAD groups. LF and HF components of HRV were increased in GH and GHD groups. However, HF component of HRV was increased in GHD as compared to GH. The pulmonary artery acceleration time was reduced in both SAD groups. In addition, SAD impaired diastolic function in both LV (GN: 5.80.19 vs GD: 8.00.29 and GH: 8.20.54 vs GHD: 13.50.84, mmHg) and RV (GN: 3.50.15 vs GD: 4.850.15 and GH: 5.830.31 vs GHD: 7.770.25, mmHg). SAD induced LV and RV hypertrophy according to LVW and RVW/BW indexes (LV:9% in GD and 10% in GHD and RV:25% in GD and 34% in GHD), as well as, SAD induced an augment in total collagen in LV (of 1.6-fold in GD and 2-fold in GHD), in RV (2.9-fold in GD and 1.15-fold in GHD), and in pulmonary artery (3.38-fold in GD and 1.53-fold in GHD). Also, SAD increased collagen gene expression type I in LV (6.7-fold in GD and 1.6-fold in GHD) and RV (5.7-fold in GD and 5.3-fold in GHD); collagen type III in LV (3-fold in GD and 2.1-fold in GHD) and RV (4.6-fold in GD and 2.4-fold in GHD). In normotensive rats, SAD increased ANP expression in LV (1.8-fold) and in RV (1.8-fold), and -skelectal in LV (3.7-fold) and RV (1.2-fold). However, GHD group only enhanced -skelectal expression in RV (1.9-fold). Our results showed that the impairment of baroreflex function by SAD, despite not changing BP, induced important adjustments of cardiac structure characterizing LV and RV hypertrophy, as well as induced pulmonary hypertension. These changes may indicate that isolated baroreflex dysfunction can modulate target-tissue damage

L’hypertension pulmonaire (HTP) est définie par une valeur de pression artérielle pulmonaire moyenne (PAPm) supérieure à 25 mmHg au repos. Il existe des formes sévères d’HTP (HTPs) avec des valeurs de PAPm encore plus élevées associées à des symptômes plus marqués et à l’apparition de lésions anatomo pathologiques spécifiques. Le diagnostic et le développement de nouvelles thérapies sont des enjeux majeurs pour une meilleure prise encharge de ces patients À l’aide de la tomodensitométrie, nos travaux observationnels chez l’homme atteint debroncho-pneumopathie chronique obstructive (BPCO) ont montré une corrélation de l’HTP avec le remodelage bronchique et non pas avec l’emphysème. L’HTPs peut être une complication rare mais grave de la BPCO. L’évaluation in vivo des modifications du lit vasculaire pulmonaire a permis de confirmer l’existence d’un phénotype particulier chez les patients atteints de BPCO compliquée d’HTPs. De plus, la définition d’un score combiné comprenant des paramètres non invasifs tomodensitométriques devrait permettre de sélectionner plus finement les patients devant subir un cathétérisme cardiaque droit.En parallèle, dans nos travaux expérimentaux, nous avons complété la caractérisation d’un modèle d’hypertension artérielle pulmonaire chez le rat développant un phénotype sévère(HTAPs) et présentant des lésions artérielles pulmonaires caractéristiques de la maladie humaine. Ce modèle, ainsi que des modèles animaux plus classiques d’HTP, nous ont permis d’identifier un rôle du facteur de croissance des nerfs NGF dans cette pathologie, dont le ciblage pourrait ouvrir de nouvelles perspectives thérapeutiques. / Pulmonary hypertension (PH) is defined by a mean pulmonary arterial pressure (mPAP) at or above 25 mmHg at rest. Severe forms of PH (sPH) are characterized by a stronger elevation of mPAP, more marked symptoms and specific pulmonary vascular lesions. Real challenges come from a better diagnosis for these patients and identification of new therapeutic targets to improve their therapeutic care. Our results show by computed tomography that PH associated to chronic obstructive pulmonary disease (COPD) is correlated to airway remodeling and not to emphysema. Severe PH is a rare and serious complication of COPD. We confirmed existence of a phenotype in COPD patients with sPH, by evaluating in vivo modifications of the pulmonary vascular bed in these patients. Moreover, we defined a combined score, which may be a non-invasive tool to select patients for right heart catheterization In parallel, we completed the characterization of a rat model of severe pulmonary arterial hypertension (sPAH) that developed a severe phenotype with pulmonary arterial specific and human-like lesions. In this model, as well as in more classical PH models, our results demonstrated an increased expression of the nerve growth factor NGF and its role in PH and sPAH pathophysiology. These results therefore suggest that NGF may be an interesting target to develop new therapeutic perspectives in this disease.

INTRODUÇÃO: Pacientes com doenças falciformes (DF) e outras anemias hemolíticas têm prevalência aumentada de hipertensão pulmonar (HP), sendo este diagnóstico associado com maior mortalidade. O objetivo deste trabalho foi estimar a prevalência desta complicação, suas características clínicas e laboratoriais e determinar o padrão hemodinâmico ao cateterismo de artéria pulmonar. MÉTODOS: Neste estudo transversal 80 pacientes consecutivos com anemia falciforme e Sb0 talassemia foram submetidos à ecocardiografia por um único observador. Os pacientes foram avaliados clinicamente, para verificar a presença de complicações associadas à DF, realizaram um teste de caminhada e realizaram exames hematológicos e bioquímicos referentes a parâmetros de hemólise, inflamação, função hepática e renal. Foi indicada avaliação hemodinâmica, com cateterismo de artéria pulmonar (Swan-Ganz), para os pacientes com velocidade de fluxo retrógrado pela tricúspide (VRT) ³2,5m/s, detectada ao ecocardiograma. A HP foi caracterizada por pressão média da artéria pulmonar ³ 25 mmHg. Os pacientes com HP foram comparados, com relação aos mesmos parâmetros prévios, ao restante da população estudada. RESULTADOS: 40% dos pacientes (32/80) apresentaram VRT³2,5m/s, sendo indicado avaliação hemodinâmica. O grupo com VRT³2,5m/s apresentou maior média etária, maior prevalência de úlceras de perna, de proteinúria e de hepatite C, menores valores de hemoglobina e de albumina, maiores valores de uréia, de creatinina, de ácido úrico, de desidrogenase lática, de aspartato aminotransferase e de gglutamiltranspeptidase do que os do grupo VRT<2,5m/s. O grupo VRT³2,5m/s apresentou também menor distância percorrida no teste de caminhada e saturação de oxigênio mais baixa tanto em repouso quanto após a caminhada. Ao ecocardiograma, este grupo apresentou maior volume atrial direito e esquerdo. 78% dos pacientes (25/32) com indicação de cateterismo se submeteram ao procedimento e em 8 deles foi confirmada HP. Dos 8 pacientes com diagnóstico de HP, 3 apresentaram hipertensão pré-capilar e os demais apresentaram hipertensão capilar (pressão de oclusão da artéria pulmonar acima de 15 mmHg). A VRT medida pelo ecocardiograma apresentou boa correlação com a medida de pressão sistólica de artéria pulmonar aferida no cateterismo (r=0,77). Os pacientes com HP confirmada apresentaram média etária maior, menores concentrações de hemoglobina e de contagem plaquetária e maiores valores de desidrogenase lática, uréia, creatinina, ácido úrico, gglutamiltranspeptidase e ferro do que o grupo sem HP. Os indivíduos com HP tiveram pior desempenho no teste de caminhada do que o grupo sem HP. Pacientes com HP apresentaram dilatação de átrio direito e esquerdo e índice cardíaco mais elevado do que o grupo sem HP. CONCLUSÕES: Pacientes com DF têm prevalência aumentada de HP detectada pelo ecocardiograma e confirmada pelo cateterismo pulmonar. O ecocardiograma é um bom instrumento de triagem. As populações separadas de acordo com o nível de VRT ao ecocardiograma apresentam diferenças clínicas e laboratoriais, sugerindo maior taxa de hemólise nas com VRT³2,5m/s. Estas diferenças se mantêm, na maior parte das situações, quando o diagnóstico de HP é confirmado. Indivíduos com diagnóstico de HP podem ter padrões hemodinâmicos de hipertensão capilar ou pré-capilar, denotando diferentes etiologias que podem implicar em diferentes abordagens terapêuticas. / INTRODUCTION: Patients with sickle cell disease (SCD) and other haemolytic anaemia have increased prevalence of pulmonary hypertension (PH) that is related to higher mortality. The aim of this stdy was to determine the prevalence of PH and, its clinical, laboratorial and hemodynamic features. METHODS: In a crosssectional study, we evaluated 80 consecutive patients with sickle cell anemia and Sb0thalassemia who were submitted to a Doppler echocardioghraphy performed by a single observer. Clinical and laboratorial data were collected for all patients in order to verify the presence of SCD complications and to evaluate haemolysis rate, inflammation, liver and renal function. All patients performed a six-minute walk test. Patients who had peak velocity of regurgitant flow of tricuspid (Vrft) of at least 2.5 m/s were referred to pulmonary artery catheterization (Swan-Ganz). PH was defined as a mean pulmonary artery pressure ³ 25 mmHg. Clinical, laboratorial and hemodynamic data of patients with confirmed PH were compared to those data of patients without PH. RESULTS: Forty percent of patients (32/80) had Vrft ³ 2.5m/s and hemodynamic evaluation was recommended. The group of patients with Vrft³2.5 m/s had higher average age, higher prevalence of leg ulcers, proteinuria and hepatitis C, lower values of hemoglobin and albumin, higher values of urea, creatinine, uric acid, lactic dehydrogenase, aspartate aminotransferase and gglutamyltranspeptidase than the group with Vrft<2.5 m.s. The group with Vrft³2.5 m/s had poorer performance on the walk test and had lowest oxygen saturation at rest and post-exercise. On echocardiography, this group had greater right and left atrial volume. Only 78% of patients (25/32) underwent pulmonary artery catheterization and, in 8 patients PH was confirmed. Among the patients with PH, 3 had pre-capillary hypertension and 5 had post-capillary hypertension (pulmonary artery occlusion pressure above 15 mmHg). The Vrft measured by echocardiogram showed good correlation with the value of systolic pulmonary artery pressure, measured on Swan-Ganz(r=0,77). The patients with confirmed PH had higher mean age, lower levels of haemoglobin and platelet count and higher values of lactic dehydrogenase, urea, creatinine, uric acid, iron and gglutamyltranspeptidase than the group without PH. Individuals with PH had poorer performance on walk test than the group without PH. Patients with PH showed increased right and left atrium volume and higher cardiac index than the group without PH. CONCLUSIONS: Patients with SCD had increased prevalence of PH detected by Doppler echocardiography and confirmed by pulmonary catheterization. The echocardiogram was a good tool for screening. Patients who had Vrft ³ 2.5m/s exhibited clinical and laboratorial data consistent with a higher hemolysis rate than those with Vrft<2.5 m/s. Individuals diagnosed with PH may have post-capillary or pre-capillary hypertension, suggesting the existence of several etiologies and the need for different therapeutic approaches.

L’exposition humaine aux particules atmosphérique (PM) est une préoccupation majeure de santé publique. La pollution particulaire est constituée de particules grossières (PM10 diamètre < 10 μm), de particules fines (PM2.5 diamètre < 2.5 μm) et de particules ultrafines (PUF ou PM0.1 diamètre < 100 nm). L’excès de mortalité constaté par les études épidémiologiques est principalement associé aux pathologies respiratoires et cardiovasculaires. Après inhalation, les particules les plus fines (PM2.5 et PUF) pénètrent profondément dans les voies respiratoires jusqu’aux alvéoles pulmonaires. Des études ont montré qu’elles peuvent franchir la barrière alvéolo-capillaire pour se retrouver dans la circulation systémique et y exercer leurs effets délétères sur les organes cibles tel que le système cardiovasculaire. La circulation pulmonaire constitue donc une cible privilégiée des particules inhalées, particulièrement les cellules endothéliales qui tapissent la lumière des vaisseaux. L’hypertension pulmonaire (HTP) est une pathologie de la circulation pulmonaire caractérisée par un remodelage des vaisseaux pulmonaires, une hyperréactivité et une inflammation. Des études récentes ont montré le rôle prépondérant du calcium et du stress oxydant dans la physiopathologie de cette maladie. Cependant, peu d’études mécanistiques visent à expliquer les effets des PM sur les cellules cibles vasculaires pulmonaires. Dans ce contexte, ce travail vise à mieux caractériser les effets cellulaires et moléculaires des particules sur les cellules endothéliales d’artères pulmonaires humaines (HPAEC). L’impact des PM2.5 et des nanoparticules (NPs) noires de carbone (FW2) sur les cellules endothéliales d’artères pulmonaires humaines entraine des dérégulations de l’homéostasie cellulaire. En effet, nos résultats montrent une augmentation significative du stress oxydant et, notamment, de la production d’anion superoxyde cytoplasmique et mitochondrial, des perturbations de la signalisation calcique, des dommages mitochondriaux, ainsi qu’un déséquilibre de la sécrétion de facteurs vasoactifs tels que le monoxyde d’azote (NO). Nous avons, également, étudié sur ces cellules cibles vasculaires pulmonaires humaines, dans des conditions physiologique et pathologique mimant l’HTP, les effets des particules sur la signalisation calcique ainsi que le rôle du stress oxydant dans les effets observés. Nous avons, dans un premier temps, développé et validé un modèle in vitro qui mime la dynamique vasculaire observée dans l’HTP. Dans une deuxième étape, nous avons observé les effets des NPs FW2, dans les deux conditions expérimentales. Nos résultats montrent, dans les cellules placées en conditions pathologiques, une augmentation significative de la production d’espèces réactives de l’oxygène (ERO) ainsi qu’une augmentation significative de la réponse pro-inflammatoire caractérisée par la sécrétion d’interleukines telles que l’IL-6 par rapport aux cellules placées en condition physiologique. De plus, la signalisation calcique semble également altérée dans les conditions pathologiques. / Human exposure to airborne particulate matter (PM) is a health risk concern. Particulate air pollution is composed of different PM: coarse particles (PM10 diameter < 10 μm), fine particles (PM2.5 diameter < 2.5 μm) and ultrafine particles (UFP) (PM0.1 diameter < 100 nm). The excess of mortality observed in several epidemiological studies is mainly associated with respiratory and cardiovascular diseases. After inhalation, the finest particles (PM2.5 and UFP) penetrate deeply into the airways, accumulate in pulmonary alveoli, cross the epithelial barrier to reach the pulmonary circulation and exert deleterious effects on the cardiovascular system. Inhaled particles are therefore observed in the pulmonary circulation, in direct contact with endothelial cells lining the inner surface of blood artery. Pulmonary Hypertension (PH) is the main disease of the pulmonary circulation characterized by remodeling of the pulmonary wall, changes in pulmonary vascular hyperactivity and inflammation. Oxidative stress and alteration in calcium signaling are also critical events involved in the physiopathology of PH. However, the effect of PM on these pulmonary vascular cellular targets is poorly described. In this context, the objectives of the present study are to assess the cellular and molecular effects of particle exposures in human pulmonary artery endothelial cells (HPAEC). Our results highlighted various cellular homeostasis alterations of HPAEC in response to PM2.5 and black carbon nanoparticles (FW2 NPs). We observed a significant increase of oxidative stress including cytoplasmic and mitochondrial superoxide anion production in concentration dependent-manner. Moreover, we observed calcium signaling alterations, mitochondrial damages, as well as a deregulation of vasoactive factors secretion such as nitric oxide (NO). Finally, we studied these cellular targets under physiological and pathological conditions mimicking PH. We have first developed a new in vitro model that mimics the vascular dynamics observed in the PH. Then, we investigated the effects of FW2 NPs in both experimental conditions. Our results showed, in pathological conditions, a significant increase in reactive oxygen species (ROS) production and a significant increase in the pro-inflammatory response characterized by interleukin secretion such as IL-6 as compared to cells in physiological condition. In addition, the calcium signaling seemed also be impaired in pathological conditions.

No description available.

A disfunção microvascular, envolvendo células endoteliais, plaquetas e leucócitos, está presente na hipertensão arterial pulmonar (HAP), associando-se a risco aumentado de trombose e menor sobrevida. Estudos sobre disfunção microvascular são escassos em outras formas da doença que não a idiopática. Os objetivos do estudo foram: caracterizar a disfunção microvascular em diferentes formas de HAP através da dosagem de marcadores bioquímicos, avaliando possíveis correlações com índices de gravidade; investigar os efeitos da administração de rosuvastatina em níveis circulantes de marcadores de disfunção microvascular nesses pacientes; e investigar possível associação entre o nível plasmático dos marcadores e prognóstico. Foram incluídos sessenta pacientes: 14 com HAP idiopática ou hereditária, e 46 com HAP associada a cardiopatia congênita (HAPCCg) sem hipoxemia (N=18) ou com hipoxemia (N=28), com idades entre 13 e 60 anos. Foram dosados os níveis plasmáticos circulantes do antígeno do fator de von Willebrand (vWF:Ag), ativador tecidual do plasminogênio (t-PA); inibidor do ativador do plasminogênio (PAI-1), fator de necrose tumoral (TNF-), proteína C reativa (PCR), selectina-P; interleucina-6 (IL-6); e interleucina-10 (IL -10), na condição basal e após 30, 60 e 180 dias de tratamento, por método imunoenzimático. Após randomização, administrouse placebo (N=30) ou dose única oral diária (10mg) de rosuvastatina (N=30), por seis meses. Dados demográficos e funcionais como idade, distância caminhada em seis minutos, saturação periférica de oxigênio em repouso e após esforço, bem como hematócrito, também foram registrados. Pacientes com HAPCCg foram acompanhados por um período de 0,7 a 4,0 anos (mediana de 3,6 anos). Na condição basal, excetuando-se TNF- e PCR, todas as proteínas apresentaram-se significantemente elevadas em relação aos controles (p<0,001), havendo correlação com índices de gravidade clínica. No estudo com rosuvastatina, houve redução significante nos níveis de selectina-P em relação ao placebo (p=0,037), ao longo do tratamento. Houve melhora na saturação periférica de oxigênio após seis minutos de caminhada, no grupo estatina, em pacientes com HAPCCg com hipoxemia, em relação ao placebo. Considerando-se o período de acompanhamento, em portadores de HAPCCg, níveis plasmáticos persistentemente elevados do vWF:Ag (média de quatro determinações), acima do nível correspondente ao percentil 95 dos controles (139 U/d/L) associaram-se maior risco de morte (razão de risco 6,56, IC 95% 1,46 a 29,4, p=0.014), sem alteração após ajustamento para variáveis demográficas, funcionais e de tratamento, à análise multivariada. Assim, a disfunção microvascular está presente em indivíduos com HAP idiopática, hereditária ou associada a cardiopatias congênitas. Na HAP, o uso crônico de rosuvastatina em dose baixa associase à redução do nível circulante de selectina-P, e propicia aumento na saturação periférica de oxigênio ao final do exercício, em indivíduos com HAPCCg e hipoxemia. Em indivíduos portadores de HAPCCg, níveis plasmáticos persistentemente elevados do vWF:Ag são indicativo de pior prognóstico / Microvascular dysfunction, involving endothelial cells, platelets and leukocytes, is present in pulmonary arterial hypertension (PAH), and is associated to higher risk to thrombotic complications and mortality. Most data about microvascular dysfunction in PAH do not include other forms of the disease beyond idiopathic PAH. The present study was planned to measure plasma levels microvascular dysfunction markers in two different forms of PAH, and investigate possible correlations with indices of severity of the disease; to investigate the effects of chronic rosuvastatin administration versus placebo on the circulating levels of these markers; and to investigate possible associations between levels of these parameters and prognosis. Sixty patients (aged 13 to 60 years) were included, 14 with idiopathic or hereditary PAH, and 46 with congenital heart disease-associated PAH (CHDPAH), in the absence (N=18) or presence (N=28) of hypoxemia. Plasma levels of von Willebrand factor antigen (vWF:Ag), tissue-plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor alpha (TNF-), reactive C protein (RCP), P-selectin, interleukin-6 (IL- 6), and interleukin-10 (IL-10) were measured before treatment and 30, 90, and 180 days on treatment using high-sensitivity enzyme-linked immunosorbent assay kits. Patients were randomly assigned to placebo (N=30) or a single oral dose of rosuvastatin (N=30), 10mg/day, for six months. Demographic and functional data such as age, six-minute walk distance, peripheral oxygen saturation at rest and at the end of the six-minute walk, as well as the hematocrit, were recorded. Patients with CHDPAH were followed-up for 0.7 to 4.0 years (median 3.6 years). At baseline, levels of all proteins (except TNF- and RCP) were significantly increased in patients versus controls (p<0,001), and correlated significantly with indices of severity of the disease. P-selectin level was lower in the rosuvastatin group compared with placebo throughout the treatment (p = 0.037). In hypoxemic CHDPAH patients, the peripheral oxygen saturation, at the end of the six-minute walk, was higher in the rosuvastatin group, compared with placebo. During the follow-up of patients with CHDPAH, an average vWF:Ag (mean of four determinations) above the level corresponding to the 95th percentile of controls (139 U/dL) was associated with a high risk of death (hazard ratio 6.56, 95% CI 1.46 to 29.4, p=0.014). This was not modified after adjustment for demographic, functional and treatment-related variables in multivariate analysis. In conclusion, microvascular dysfunction is present in individuals with idiopathic, hereditary and the congenital heart disease-associated PAH. The chronic use of low-dose rosuvastatin is associated to reduction of circulating levels of P-selectin. In patients with CHDPAH with hypoxemia, rosuvastatin also increases peripheral oxygen saturation during exercise. In CHDPAH patients, a sustained increase in plasma vWF:Ag is indicative of poor prognosis

La circulation extracorporelle (CEC) déclenche une réaction inflammatoire systémique, un dommage d’ischémie-reperfusion (I-R) et une dysfonction de l’endothélium dans la circulation pulmonaire. L’hypertension pulmonaire (HTP) est la conséquence de cette cascade de réactions. Cette HTP augmente le travail du ventricule droit et peut causer sa dysfonction, un sevrage difficile de la CEC et une augmentation des besoins de vasopresseurs après la chirurgie cardiaque. L’administration de milrinone et d’époprosténol inhalés a démontré une réduction de la dysfonction endothéliale dans l’artère pulmonaire. Le but de ce travail est d’évaluer différents types de nébulisateur pour l’administration de la milrinone et d’évaluer l’effet du traitement préventif de la combinaison de milrinone et époprosténol inhalés sur les résultats postopératoires en chirurgie cardiaque. Deux études ont été conduites. Dans la première, trois groupes de porcelets ont été comparés : (1) groupe milrinone avec nébulisateur ultrasonique ; CEC et reperfusion précédées par 2,5 mg de milrinone inhalée, (2) goupe milrinone avec nébulisateur à simple jet ; CEC et reperfusion précédées par 2,5 mg de milrinone inhalée et (3) groupe contrôle ; CEC et reperfusion sans traitement. Durant la procédure, les paramètres hémodynamiques, biochimiques et hématologiques ont été mesurés. Après sacrifice, la relaxation endothélium dépendante de l’artère pulmonaire à l’acétylcholine et à la bradykinine a été étudiée en chambres d’organe. Nous avons noté une amélioration de la relaxation de l’endothélium à la bradykinine et à l’acétylcholine dans le groupe avec inhalation de milrinone avec le nébulisateur ultrasonique. Dans la deuxième étude, une analyse rétrospective de 60 patients à haut risque chirurgical atteints d’HTP et opérés à l’Institut de Cardiologie de Montréal à été effectuée. Deux groupes ont été comparés : (1) 40 patients ayant reçu la combinaison de milrinone et d’époprosténol inhalés avant la CEC (groupe traitement) et (2) 20 patients avec des caractéristiques préopératoires n’ayant reçu aucun traitement inhalé avant la CEC (groupe contrôle). Nous avons observé que les besoins en support pharmacologique vasoactif était réduit à 12 heures et à 24 heures postopératoires dans le groupe traitement. L’utilisation de la nébulisation ultrasonique a un impact favorable sur l’endothélium de l’artère pulmonaire après la CEC lorsque comparée à la nébulisation standard à simple jet. Le traitement préventif des patients atteints d’HTP avec la combinaison de milrinone et d’époprosténol inhalés avant la CEC est associé avec une diminution importante des besoins de support vasoactif aux soins intensifs dans les 24 premières heures après la chirurgie. / Cardiopulmonary bypass (CPB) triggers a systemic inflammatory response, an ischemia-reperfusion (I-R) injury and endothelial dysfunction in the pulmonary circulation. Pulmonary hypertension (PH) is a consequence of this insult. The latter increases right ventricle work and may cause difficult separation from cardiopulmonary bypass (CPB) and increased vasoactive requirements after cardiac surgery. Administration of inhaled milrinone or epoprostenol has been shown to reduce endothelial dysfunction in the pulmonary artery. The aim of this work is to evaluate different nebulisators for the administration of milrinone and to evaluate the effect of pre-emptive treatment with inhaled milrinone and epoprostenol on postoperative outcome in cardiac surgery. Two different studies were done. In the first, three groups of swine were compared: (1) ultrasonic nebulisator inhaled milrinone group; CPB and reperfusion preceded by 2.5 mg inhaled milrinone, (2) simple jet nebulisator inhaled milrinone group; CPB and reperfusion preceded by 2.5 mg inhaled milrinone, and (3) control group; CBP 90 minutes followed by 60 minutes of reperfusion without treatment. During the procedure, hemodynamic, biochemical and hematologic parameters were measured. After sacrifice, pulmonary arterial endothelium-dependent relaxations to acetylcholine and bradykinin were studied in organ chamber experiments. There was a greater improvement in endothelium-dependent relaxations to bradykinin and acetylcholine in the ultrasonic nebuliser inhaled milrinone group compared with the control group and the simple jet nebulisator inhaled milrinone group. In the second study, a retrospective analysis of 60 high-risk surgical patients with PH operated at the Montreal Heart Institute was conducted. Two groups were compared: (1) 40 patients received both inhaled milrinone and inhaled epoprostenol before CPB (treatment group); (2) 20 patients with equivalent preoperative data did not receive any inhaled medication before CPB during the same period (control group). Post-operative vasoactive requirement was reduced at 12 hours and 24 hours post-operatively in the treatment group. Use of ultrasonic nebulisation has a favourable impact on the pulmonary endothelial dysfunction induced by CPB when compared to the simple jet nebulisation traditionally used. Pre-emptive treatment of PH with a combination of inhaled milrinone and epoprostenol prior to CPB was associated with a significant reduction in vasoactive support in the intensive care unit during the first 24 hours after cardiac surgery.

L’hypertension pulmonaire (HP) est une maladie dont l’étiologie est inconnue et qui entraîne ultimement une défaillance du ventricule droit (VD) et le décès. L’HP peut être induite chez le rat par la la monocrotaline (MCT), un alcaloïde pyrrolizidique extrait de la plante Crotalaria Spectabilis, causant des lésions à l’endothélium des artères pulmonaires, menant à un épaississement de ces dernières et à une augmentation de la résistance vasculaire. Ceci à pour conséquence de causer une hypertrophie du VD, de l’inflammation, une dysfonction endothéliale NO-dépendante des artères coronariennes et une augmentation des peptides natriurétiques circulants. Objectif: Nous avons testé l’hypothèse selon laquelle l’étiopathologie de l’HP impliquerait le récepteur à ocytocine (OTR) dû à son implication fonctionnelle avec les cytokines inflammatoires et la libération du peptide natriurétique atrial (ANP) et du NO. Méthodes: Des rats mâles Sprague-Dawley pesant 220-250g reçurent une seule injection sous-cutanée de MCT (60 mg/kg). 6 à 7 semaines (46±1 jours) suivant l’injection, les rats furent sacrifiés et l’expression génique et protéique fut déterminée par PCR en temps réel et par western blot, respectivement, dans le VD et le ventricule gauche (VG) Résultats: Les rats traités au MCT démontrèrent une augmentation significative du VD. Une hypertrophie du VD était évidente puisque le ratio du VD sur le VG ainsi que le poids du septum étaient près de 77% plus élevés chez les rats traités au MCT que chez les rats contrôles. Le traitement au MCT augmenta l’expression génique d’ANP (3.7-fois dans le VG et 8-fois dans le VD) ainisi que le NP du cerveau (2.7-fois dans le VG et 10-fois dans le VD). Les transcrits de trois récepteurs de NP augmentèrent significativement (0.3-2 fois) seulement dans le VD. L’expression protéique de la NO synthase (iNOS) fut également augmentée de façon sélective dans le VD. Par contre, les transcripts de NOS endothéliale et de NOS neuronale étaient plus élevés (0.5-2 fold) dans le VG. L’ARNm et l’expression protéique d’OTR furent diminués de 50% dans le VD, tandis qu’une augmentation de l’expression des cytokines IL-1β and IL-6 fut observée. L’ARNm de Nab1, un marqueur d’hypertrophie pathologique, fut augmentée de deux-fois dans le VD. Conclusion: L’augmentation d’expression génique de NP dans le VD des rats traités au MCT est associée à une augmentation des transcripts du récepteur NP, suggérant une action locale de NP dans le VD durant l’HP. L’expression d’OTR est atténuée dans le VD, possiblement par des cytokines inflammatoires puisque le promoteur du gène de l’OTR contient de multiples éléments de réponse aux interleukines. Diminuer l’expression d’OTR dans le VD durant l’hypertension pulmonaire pourrait influencer de manière positive la fonction cardiaque car l’OTR régule la contractilité et le rythme cardiaque. Mots clés: hypertension pulmonaire, hypertrophie du ventricule droit monocrotaline, récepteur à ocytocine, inflammation, peptides natriurétiques. / Pulmonary hypertension (PH) is a disease of unknown etiology that ultimately causes failure of right ventricle (RV) with a lethal outcome. PH can be induced in the rat with monocrotaline (MCT), a pyrrolizidine alkaloid from the plant Crotolaria spectabilis that damages the pulmonary artery endothelium leading to thickening of the pulmonary arteries and increased vascular resistance. This subsequently results in RV hypertrophy, inflammation, nitric oxide (NO)-associated coronary endothelial dysfunction and increment of natriuretic peptides (NP) in the circulation. Objective: We verified hypothesis that the etiopathogenesis of PH involves the oxytocin receptor (OTR) because of its functional association with inflammatory cytokines and release of atrial natriuretic peptide (ANP) and NO. Methods: Male Sprague-Dawley rats weighing 220-250g received a single subcutaneous injection of 60 mg/kg of MCT. Six to 7 weeks (46±1 days) following the injection, rats were sacrificed and gene and protein expression were detected by real-time PCR and western-blot analysis, respectively, in the RV and LV (left ventricle). Results: MCT-treated rats displayed significant increases in RV weight. RV hypertrophy was evident as the ratio of the RV to LV plus septum weight was nearly 77% higher in MCT-treated rats compared to control rats. MCT treatment increased transcripts of ANP (3.7-fold in the LV and 8-fold in RV) and brain NP (2.7-fold in the LV and 10-fold in RV). Transcripts for three NP receptors significantly increased (0.3-2 fold) only in the RV. iNOS (inducible NO synthase) protein expression also increased selectively in the RV. In contrast, the endothelial NOS and neural NOS transcripts heightened (0.5-2 fold) in the LV. Both OTR mRNA and protein were decreased by 50% in the RV, whereas an up-regulation of cytokines IL-1β and IL-6 was observed. Nab1 mRNA, a marker of pathological hypertrophy, increased two-fold in the RV. Conclusion: Increased gene expression of NP in the RV of the MCT-treated rat correlates with upregulation of NP receptor transcripts indicating local NP action in the RV during PH. OTR expression is decreased in the RV possibly by inflammatory cytokines, IL-1 and IL-6 because OTR promoter region contains multiple putative interleukin-response elements. Lowering OTR in RV during pulmonary hypertension can influence cardiac function since OT regulates heart rate and cardiac contractility and is linked with cardioprotective system ANP and NO. Keywords: pulmonary hypertension, right ventricular hypertrophy, monocrotaline, oxytocin receptor, inflammation, natriuretic peptides.

Chaque année, environ 1 à 1,25 million d’individus subiront une chirurgie cardiaque. [1] Environ 36 000 chirurgies cardiaques sont effectuées au Canada et 8000 procédures au Québec (http://www.ccs.ca). Le vieillissement de la population aura pour conséquence que la chirurgie cardiaque sera offerte à des patients de plus en plus à risque de complications, principalement en raison d’une co-morbidité plus importante, d’un risque de maladie coronarienne plus élevée, [2] d’une réserve physiologique réduite et par conséquent un risque plus élevé de mortalité à la suite d’une chirurgie cardiaque. L’une des complications significatives à la suite d’une chirurgie cardiaque est le sevrage difficile de la circulation extracorporelle. Ce dernier inclut la période au début du sevrage de la circulation extracorporelle et s’étend jusqu’au départ du patient de la salle d’opération. Lorsque le sevrage de la circulation extracorporelle est associé à une défaillance ventriculaire droite, la mortalité sera de 44 % à 86 %. [3-7] Par conséquent le diagnostic, l’identification des facteurs de risque, la compréhension du mécanisme, la prévention et le traitement du sevrage difficile de la circulation extracorporelle seront d’une importance majeure dans la sélection et la prise en charge des patients devant subir une chirurgie cardiaque. Les hypothèses de cette thèse sont les suivantes : 1) le sevrage difficile de la circulation extracorporelle est un facteur indépendant de mortalité et de morbidité, 2) le mécanisme du sevrage difficile de la circulation extracorporelle peut être approché d’une façon systématique, 3) la milrinone administrée par inhalation représente une alternative préventive et thérapeutique chez le patient à risque d’un sevrage difficile de la circulation extracorporelle après la chirurgie cardiaque. / Every year, 1 million to 1.25 million patients worldwide undergo cardiac surgery. [1] Up to 36,000 cardiac surgeries are performed each year in Canada and close to 8000 in Quebec (http://www.ccs.ca). Because of the aging of the population, cardiac surgery will increasingly be offered to patients at a higher risk of complications. Indeed, elderly patients have increased co-morbidities, and aging is also a significant risk factor in the prevalence of coronary artery disease. [2] The consequence is a reduced physiologic reserve, hence an increased risk of mortality. These issues will have a significant impact on future healthcare costs, because our population undergoing cardiac surgery will be older and more likely to develop postoperative complications. One of the most dreaded complications in cardiac surgery is difficult separation from cardiopulmonary bypass (CPB). The definition of difficult separation from CPB includes the time period from when CPB is initiated and until the patient leaves the operating room. When separation from CPB is associated with right ventricular failure, the mortality rate will range from 44% to 86%. [3-7] Therefore the diagnosis, the preoperative prediction, the mechanism, prevention and treatment of difficult separation from CPB will be crucial in order to improve the selection and care of patients and to prevent complications for this high-risk patient population. The hypotheses of this thesis are the following: 1) difficult separation from CPB is an independent factor of morbidity and mortality, 2) the mechanism of difficult separation from CPB can be understood through a systematic approach, 3) inhaled milrinone is a preventive and therapeutic approach in the patient at risk for difficult weaning from CPB after cardiac surgery.

INTRODUÇÃO: A hipertensão pulmonar tromboembólica crônica (HPTEC) é uma doença vascular pulmonar progressiva, cuja incidência varia de 0,56% a 3,2% em indivíduos com embolia pulmonar aguda (EPA) recorrente. Apesar do avanço nas opções de tratamento para HPTEC, a tromboendarterectomia pulmonar (TEAP) continua sendo padrão ouro, levando a melhora hemodinâmica e aumento da sobrevida. OBJETIVOS: Avaliar o impacto que mudanças técnicas intraoperatórias implementadas tiveram na evolução dos pacientes submetidos à TEAP em relação à morbimortalidade imediata e tardia, e também sobre o desenvolvimento do ato operatório. MÉTODOS: Estudo retrospectivo em portadores de HPTEC, submetidos à TEAP, no período de janeiro/2007 a maio/2016, divididos em 3 grupos, de acordo com intervenções implementadas. A 1ª intervenção consistiu em mudanças na circulação extracorpórea (CEC) e no tempo de parada circulatória total (PCT), e a 2ª intervenção incluiu alterações na CEC, técnicas anestésica e cirúrgica. A avaliação dos dados incluiu análise univariada para associações entre intervenções com variáveis de morbimortalidade e técnica operatória. O modelo de regressão multivariado foi aplicado para validar se as melhorias resultaram das intervenções implementadas. A análise de sobrevida foi feita por Kaplan-Meier. RESULTADOS: Foram avaliados 102 indivíduos, 62,8% mulheres, idade média de 49,1±14,8 anos, 65,7% estavam em classe funcional III-IV (NYHA). A avaliação hemodinâmica demonstrou hipertensão pulmonar importante, com valores médios elevados de pressão média na artéria pulmonar (PmAP; G1=52,9±14,45mmHg; G2=53,2±12,4mmHg; G3=53,3±12,5mmHg, p=0,992) e resistência vascular pulmonar (RVP; G1=828,4±295,13 dynas.s.cm-5; G2=838,9±428,4 dynas.s.cm-5; G3=969±417,3 dynas.s.cm-5, p=0,313). Os pacientes submetidos à TEAP mostraram aumento do tempo total de CEC entre os grupos (G1=192,3±39,4min; G2=251,7±33,4min; G3=298,2±40,2min, p < 0,001), como resultado da padronização dos tempos de esfriamento (G1=47,9±18,5min; G2=66,9±5,9min; G3=70,6±3,7min, p < 0,001), aquecimento (G1=66,8±17,7min; G2=87,2±8,1min; G3=107,7±23,5min, p < 0,001) e reperfusão (G1=25,5±7,6min; G2=20,7±8,4 min; G3=18,6±9,4min, p=0,007). A diminuição do número de operações com mais de 2 PCT (G1= 89%; G2= 60%; G3: 55%, p=0,002) foi decorrente do aumento da duração média de cada PCT (G1=15,5±2,9min; G2=17,8±1,7min; G3=19,2±2,0min, p < 0,001). Complicações pós-operatórias foram observadas em 88,5% dos pacientes, havendo redução significativa das complicações cirúrgicas (p=0,035), infecciosas (p=0,017) e neurológicas com sintomas permanentes (p=0,048) na comparação entre os 3 grupos. No seguimento após a alta, 85% estavam em classe funcional I-II (NYHA), sem melhora hemodinâmica significativa entre os grupos. Após a análise multivariada, o G3 apresentou 4,7 menos chances de complicação cirúrgica que G1 (p=0,034) e tempo de aquecimento menor que 83 minutos aumentou 4 vezes a chance de complicação infecciosa (p=0,002). A redução da mortalidade hospitalar e da sobrevida não foi significativa entre os grupos. CONCLUSÕES: Em relação à morbimortalidade imediata e tardia, o impacto das intervenções foi evidenciado pela redução das complicações neurológicas com sintomas permanentes, complicações cirúrgicas e infecciosas. Em relação ao ato operatório, o impacto foi evidenciado pelo aumento dos tempos totais de CEC, de esfriamento, de aquecimento, tempo médio das PCT, redução nos números de PCT e no tempo total de reperfusão / INTRODUCTION: Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive pulmonary vascular disease which incidence varies from 0.56% to 3.2% in individuals with recurrent acute pulmonary embolism (APE). Despite advances in treatment options for CTEPH, pulmonary endarterectomy (PE) remains a gold standard, leading to hemodynamic improvement and increased survival. OBJECTIVES: Evaluate the impact of intraoperative technical changes on the evolution of patients submitted to PE related to immediate and late morbimortality, as well as on the development of the operative procedure. METHODS: Retrospective study of patients with CTEPH, submitted to PE, between January 2007 and May 2016, divided into 3 groups, according to the implemented interventions. The first intervention consisted of changes in cardiopulmonary bypass (CPB) and total circulatory arrest time (CAT), and the second intervention included changes in CPB, anaesthetic and surgical techniques. The data analysis included a univariate analysis for associations between interventions with morbidity variables and operative technique. The multivariate regression model was applied to validate whether the improvements resulted from the interventions implemented. Survival analysis was performed using Kaplan-Meier. RESULTS: We evaluated 102 individuals, 62.8% were women, mean age was 49.1 ± 14.8 years, and 65.7% were in functional class III-IV (NYHA). The hemodynamic evaluation showed significant pulmonary hypertension, with mean values of mean pulmonary artery pressure (mPAP, G1 = 52.9 ± 14.45 mmHg, G2 = 53.2 ± 12.4 mmHg, G3 = 53.3 ± 12.5 mmHg, p = 0.992) and pulmonary vascular resistance (PVR, G1 = 828.4 ± 295.13 dynas.s.cm-5, G2 = 838.9 ± 428.4 dynas.s.cm-5, G3 = 969 ± 417.3 dynas.s.cm-5, p = 0.313). The patients submitted to PE showed an increase in the total CPB time between the groups (G1 = 192.3 ± 39.4min, G2 = 251.7 ± 33.4min, G3 = 298.2 ± 40.2min, p < 0.001), as a result of the standardization of cooling times (G1 = 47.9 ± 18.5min, G2 = 66.9 ± 5.9min, G3 = 70.6 ± 3.7min, p < 0.001), heating (G1 = 66.8 ± 17.7min, G2 = 87.2 ± 8.1min, G3 = 107.7 ± 23.5min, p < 0.001) and reperfusion (G1 = 25.5 ± 7.6min, G2 = 20.7 ± 8.4 min, G3 = 18.6 ± 9.4min, p = 0.007). The decrease in the number of operations with more than 2 CAT (G1 = 89%, G2 = 60%, G3: 55%, p = 0.002) was due to the increase in the average duration of each CAT (G1 = 15.5 ± 2, 9min, G2 = 17.8 ± 1.7min, G3 = 19.2 ± 2.0min, p < 0.001). Postoperative complications were observed in 88.5% of the patients, with a significant reduction in surgical (p = 0.035), infectious (p = 0.017) and neurological complications with permanent symptoms (p = 0.048) in the comparison between the three groups. In the post-discharge follow-up, 85% were in functional class I-II (NYHA), with no significant hemodynamic improvement between groups. After the multivariate analysis, G3 presented 4.7 less chance of surgical complication than G1 (p = 0.034) and warming time less than 83 minutes increased 4 times the chance of infectious complication (p = 0.002). The reduction in hospital mortality and survival was not significant between the groups. CONCLUSIONS: Regarding immediate and late morbimortality, the impact of interventions was evidenced by the reduction of neurological complications with permanent symptoms, surgical and infectious complications. Regarding the operative event, the impact was evidenced by the increase in total CPB, cooling, heating, mean CAT time, CAT reduction and total reperfusion time